EVE Health Group Limited

WE MAKE GENERIC DRUGS BETTER.

THURSDAY, 12 NOVEMBER 2026

INVESTOR WEBINAR
BUSINESS UPDATE

ASX: EVE

Who We Are

DEDICATED TO IMPROVING GENERIC DRUGS FOR PATIENTS.

The Company

An ASX-listed Australian life sciences company building a commercial-stage pharmaceutical reformulation business. Products are supplied under SAS-B while the portfolio advances toward full product registration.

Commercial-stage. Australian. Ready to scale.

Why Reformulate?

EVE targets established medicines where formulation can reduce real patient and prescriber friction - including variable response, swallowing difficulty and combination-treatment burden.

Better delivery solves real patient friction.

Our Skill Set

Patent-pending nano-emulsion formulation science, regulatory strategy and commercial execution focused on high-value, poorly soluble medicines and scalable partner channels.

A mature platform built to repeat.

© EVE HEALTH GROUP 2026

The Erectile Dysfunction Market Opportunity

A LARGE, GROWING MARKET WITH HIGH DISCONTINUATION AND NO ESTABLISHED FAST-ONSET ORAL ALTERNATIVE.

322m
Men globally affected by ED (projected 2025) [1]

USD 5.7B
Global ED treatment market size (2026) [2]

~50%
Patients discontinue PDE5Is within one year [3]

~61%
Australian men 45+ reporting some degree of ED [4]

Market Scale

~5.4M Australian men aged 45+ (June 2025), of whom ~1 in 3 report moderate or complete ED [4]. Australian compounding market ~US$107M (2024) [5].

The Discontinuation Problem

Timing, planning and inconsistent response create friction.
EVE is focused on patients whom current formats do not serve well.



AUSTRALIA → THE WORLD

A meaningful patient need, a growing global market, and a clear delivery-format opportunity for EVE's patent-pending platform.

[1] Aytaç et al., BJU Int. 1999 (2025 projection). [2] Coherent Market Insights, 28 Apr 2026 (US$5.67B rounded). [2] also forecasts US$9.59B by 2033. [3] Corona et al. 2016 (4% per month; almost 50% after one year).
[4] Weber et al., MJA 2013; NSW 45 and Up cohort n=108,477; prevalence subset n=101,674 without prior prostate cancer. Not a current national survey. ABS ERP, 30 June 2025. [5] Credence Research (2024).

© EVE HEALTH GROUP 2026

Current Treatment Failures

WHY CONVENTIONAL TREATMENTS DRIVE PATIENT DISCONTINUATION.

Drug	Brand / format	Generic	Typical onset	Patient friction
Sildenafil	Viagra	Yes	1 hr+	Food effect / planning burden
Tadalafil	Cialis	Yes	1 hr+	Long duration, slower onset
Vardenafil	Levitra	Yes	45–60 min	Timing variability remains

30–35%
Patients report an inadequate or variable response

1 hr+
Typical onset time for conventional tablets

Up to 35%
Food effect reported for selected tablet formats

We're not fighting for share — we're picking up patients the incumbents are already losing. Libbo delivers the same active ingredient transmucosally, with onset in approximately 15 minutes.

** Onset is based on formulation design and an early 10-person observational study. Clinical validation will follow via a pilot PK study (dosing targeted Q4 2026) and a planned bioequivalence study.*

© EVE HEALTH GROUP 2026

Libbo — The Solution

VARDENAFIL ORAL DISSOLVING FILM: A REFORMULATED MEDICINE BUILT AROUND PATIENT CONVENIENCE.

What It Is

Vardenafil ODF: an established active ingredient in a fast-dissolving format.

How It Works

Nano-emulsion solubilisation supports transmucosal absorption.

Early Clinical Evidence

Early observational evidence informs the proposition; BE is the confirming next step.

Commercial Traction

LibX.com.au, telehealth and pharmacy partners form a live SAS-B pathway.



ORAL DISSOLVING FILM | TRANSMUCOSAL DELIVERY

LibX.com.au is EVE's patient education connection to prescribers.

ONSET COMPARISON


Standard swallowed tablets	Libbo
45–60 minutes	~15 minutes (based on formulation design; clinical validation pending)

Libbo absorbs transmucosally through the mouth — bypassing the gut and first-pass liver metabolism that slow conventional tablets.

© EVE HEALTH GROUP 2026

One Platform. Many Compounds.

A REPEATABLE NANO-EMULSION PROCESS FOR HIGH-VALUE POORLY SOLUBLE DRUGS.



Insoluble Molecules

A proven compound with poor aqueous solubility limits conventional tablet performance.

Nano-emulsion Solubilisation

Proprietary process converts molecules into a stable nano-emulsion with improved effective solubility.

Oral Film or Oral Spray Delivery

Film and spray formats support fast, convenient transmucosal delivery.

Faster Onset, Improved Bioavailability

More consistent systemic exposure can improve patient outcomes.

- ✓ Enhanced Solubility
- ✓ Improved Bioavailability
- ✓ Fast-Onset Formats
- ✓ Patent-Pending
- ✓ Versatile
- ✓ Reduced Patient Variability

Proprietary nano-emulsion system - turn one proven product into a platform that keeps producing.
Libbo is proof of concept. The platform is the asset.

© EVE HEALTH GROUP 2026

Validation Infrastructure Already Built

AHEAD OF FULL PRODUCT REGISTRATION, THE END-TO-END PATHWAY IS OPERATING TODAY.

Patient Education Platform
www.libx.com.au

›

Telehealth Consult
Established Australian telehealth networks

›

Prescription
Compliant clinical pathway

›

Pharmacy Fulfilment
Licensed pharmacy fulfilment

›

Home Delivery
Patient receives product with discreet delivery

- ✓ Patient acquisition model established
- ✓ Telehealth prescribing workflow proven
- ✓ Pharmacy logistics execution confirmed
- ✓ Regulatory compliance processes tested

PARTNER-LED GLOBAL ROLLOUT

Preliminary partner discussions are underway across Asia, the Middle East, Europe and North America. Post-registration rollout is designed around established partner channels.

EVE has signed an exclusive Australian compounding agreement with Optimal Pharmacy Plus Stafford — a third commercial pathway alongside SAS-B and future full registration.

The operating pathway is in place - full commercial deployment can scale through established partner channels after registration.

© EVE HEALTH GROUP 2026

The Optimal Compounding Agreement

A binding agreement with Optimal Pharmacy Plus Stafford, entering an Australian compounding channel served largely by generic sildenafil / tadalafil blends (EVE assessment).

The science stays with EVE

IP retained. Patent-pending nano-emulsion technology; EVE retains all IP, product and formulation rights, including improvements made under the Agreement.

Exclusive Australian compounder. From first supply, Optimal is EVE's exclusive Australian compounder of the initial men's sexual health range. Optimal is restricted from compounding competing formulations.

Independent of the Libbo registration pathway. The Agreement does not affect Libbo®'s bioequivalence and registration program; it is a separate commercial channel.

Capital-light. Partner-led.

75% EVE **25% Optimal**

EVE receives 75% of profit available for distribution after direct costs of compounding and delivery (Optimal 25%). No upfront fees payable by EVE.

Partner-led distribution. Telehealth partners introduced by EVE will contract directly with Optimal for fulfilment.

Three channels, one patent-pending platform. SAS-B is active today and the Optimal compounding agreement is signed, with first supply pending. Full product registration follows the bioequivalence study.

Signed 10 November 2026. First supply is subject to conditions, including technology transfer and validation. No minimum volumes or guaranteed revenue; EVE cannot yet estimate revenue.

© EVE HEALTH GROUP 2026

The Men's Sexual Health Compounding Range

COMPOUNDED FORMULATIONS ON EVE'S PATENT-PENDING NANO-EMULSION BASE FOR ED, PE AND BOTH TOGETHER.

Erectile Dysfunction

Vardenafil ED formulation.

ODF / Oral Spray

Mechanism: Vardenafil (established PDE5 inhibitor) delivered transmucosally via EVE's patent-pending nano-emulsion technology.

Positioning: Designed as a faster-acting alternative to swallowed PDE5 tablets (subject to validation).

Patient fit: The ~50% of patients who discontinue conventional PDE5 tablets within a year.

Premature Ejaculation

PE formulation on the vardenafil base.

ODF / Oral Spray

Mechanism: PE active delivered via the same nano-emulsion platform, on the vardenafil base.

Positioning: Designed as a faster-acting alternative to tablet-format PE products (subject to validation).

Patient fit: PE is one of the most common male sexual dysfunctions.

ED / PE Combination

ED + PE in one preparation.

ODF / Oral Spray

Mechanism: Single-format combination addressing both conditions in one compounded preparation.

Positioning: ED and PE often occur together; one preparation instead of two.

Patient fit: Men whose prescriber is treating both conditions.

Oral film and oral spray formats. Comparative performance remains subject to validation.

One patent-pending platform. Three men's sexual health products in the initial range. Further products may be added by agreement.

© EVE HEALTH GROUP 2026

The Patent Cliff

HIGH-VALUE MEDICINES LOSING EXCLUSIVITY CREATE DIFFERENTIATED REFORMULATION WINDOWS.

Target medicine	Global sales	Patent expiry†	EVE relevance
Apixaban (Eliquis)	USD 12.2B	2026	Pre-BE development
Rivaroxaban (Xarelto)	USD 6.8B	2025	Screening
Xtandi (Enzalutamide)	USD 6.3B	2027	Screening
Farxiga (Dapagliflozin)	USD 6.0B	2025	Screening
Imbruvica (Ibrutinib)	USD 4.9B	2027	Screening

WHY THESE TARGETS? EVE screens medicines with established demand, approaching loss of exclusivity and a credible delivery-format advantage.

** Pending BE study. Market values are directional, based on referenced 2023/2024 global sales sources. † Indicative; varies by jurisdiction (e.g. US generic apixaban entry expected 2028).*

Libbo is setting the path. The patent cliff creates a focused pipeline of established-medicine reformulation opportunities.

© EVE HEALTH GROUP 2026

Accelerated Pathway

A CAPITAL-EFFICIENT ROUTE TO PRODUCT REGISTRATION FOR ESTABLISHED MEDICINES.

Conventional new-drug development: Phase I → Phase II → Phase III → 10–15 years → hundreds of millions of dollars.

VS

Identify
High-value BCS Class II/IV candidate

›

Apply EVE's Technology
Nano-emulsion solubilisation

›

Product Validation
Real prescriber and patient feedback

›

BE Study
Confirming clinical-validation step

›

Registration
Scaled partner-led deployment

EVE's path focuses on bioequivalence for established molecules – faster, lower risk and more cost effective.

The Optimal compounding agreement sits alongside this pathway, with potential for revenue and real-world data ahead of registration.

© EVE HEALTH GROUP 2026

Multiple Pillars, One Platform

LIBBO ANCHORS THE PORTFOLIO. ONE PLATFORM DRIVES MULTIPLE FRANCHISES AND FUTURE PROGRAMS.

EVE's portfolio is structured around multiple complementary programs — all running off the same nano-emulsion platform.

MEN'S HEALTH FRANCHISE

Libbo (Patent-pending Vardenafil ODF)	*Erectile Dysfunction* TGA SAS-B AVAILABLE
PE Program	*Premature Ejaculation* IN DEVELOPMENT
ED/PE Combination	*Combined ED & PE* IN DEVELOPMENT
BPH Program	*Combination Drug Film* IN DEVELOPMENT

CARDIO-METABOLIC & FUTURE PROGRAMS

Apixaban Reformulation	*Anticoagulation* PRE-BE DEVELOPMENT
Rosuvastatin Reformulation	*Lipid Lowering* IN DEVELOPMENT
Atorvastatin Reformulation	*Lipid Lowering* IN DEVELOPMENT

The signed Optimal compounding agreement covers a separate range of compounded nano-emulsion vardenafil formulations. It does not include Libbo, whose registration program continues independently. The PE, ED/PE combination and BPH programs remain in development.

© EVE HEALTH GROUP 2026

Key Milestones & Catalysts

NEAR-TERM VALUE INFLECTION POINTS ACROSS THE PORTFOLIO.

Timing	Milestone	Detail
Completed	Compounding Agreement Signed	Binding Master Compounding and Profit Share Agreement executed with Optimal Pharmacy Plus Stafford in November 2026 for EVE's men's sexual health range.
Near-term	First Compounded Supply	Completion of technology transfer and validation with Optimal, followed by first compounded supply to patients via Australian telehealth partners.
Q1 2027	BE Study Commences	Subject to satisfactory pilot outcomes (dosing targeted Q4 2026, data early 2027), Libbo pivotal bioequivalence study targeted to commence.
H1 2027	PE Program Update	Pre-BE progress update on standalone premature ejaculation program.
H2 2027	Apixaban Pre-BE	Completion of pre-BE work on Apixaban reformulation program.
H2 2027	Registration Submission	Potential Libbo product registration submission following BE study completion, subject to clinical and regulatory outcomes.

Timing reflects the current corporate planning view and is subject to clinical, regulatory and operational dependencies.

Timing of first compounded supply is subject to completion of readiness steps including technology transfer and validation.

© EVE HEALTH GROUP 2026

Why Invest in EVE

A PRODUCT-LED PLATFORM WITH MULTIPLE PATHS TO VALUE CREATION.

Product in Use

Libbo shows how the platform can improve delivery of a known medicine.

IP Portfolio

Patent applications lodged over EVE's proprietary formulation platform.

*Patents Pending

Vast Market

ED, men's health and patent-cliff molecules create meaningful opportunity.

Scalable Model

Capital-light and partner-led, with no manufacturing or compounding infrastructure for EVE to fund.

SAS-B Revenue (today) + Compounding (signed Optimal agreement; first supply pending) → Licensing (discussions preliminary) → Scaled Partner-Led Revenue (post-registration)

Preliminary partner discussions are underway across Asia, the Middle East, Europe and North America.

A lean, R&D and regulatory-focused model designed to scale through partners.

© EVE HEALTH GROUP 2026

Corporate Snapshot


Snapshot

ASX Ticker	EVE
Share Price (10 Nov 2026)	A$0.014
Shares on Issue	352m
Options on Issue	165m (4-6 cent exercise price)
Market Capitalisation (10 Nov 2026)	A$4.9m
Cash (30 Sept 2026)	A$0.84m
Enterprise Value	A$4.1m
Debt (10 Nov 2026)	Nil

Board	Role
Rodney Hannington	Non-Executive Chairman
Dr Stuart Gunzburg	Executive Director & Chief Scientific Officer
Bill Fry	Non-Executive Director

Management	Role
Ben Rohr	Chief Executive Officer
Steven Jackson	Chief Financial Officer & Company Secretary

Ownership



© EVE HEALTH GROUP 2026

EVE Health Group

Generic medicines, reimagined through patent-pending delivery science.

WWW.EVEHEALTHGROUP.COM.AU

© EVE HEALTH GROUP 2026

Important Notice & Disclaimer

This presentation (Presentation) has been prepared by EVE Health Group Limited ABN 89 106 523 611 (EVE or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this Presentation is subject to change without notice and, subject only to any legal obligations to do so, EVE does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and similar expressions are intended to identify forward-looking statements. Forward-looking statements, opinions and estimates are based on assumptions and contingencies subject to change without notice and involve known and unknown risks, uncertainties and factors beyond the control of EVE, its directors and management. Actual results, performance or achievements may differ materially from those expressed or implied. Recipients are cautioned not to place undue reliance on forward-looking statements. Except as required by law or regulation, none of EVE, its representatives or advisers undertakes any obligation to update this Presentation.

Not an offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. It is for information purposes only and should not be considered an offer, solicitation, inducement, recommendation or invitation to acquire EVE securities or any other financial products.

Not financial product advice

This Presentation is not financial product or investment advice or a recommendation to acquire EVE securities. It has been prepared without taking into account the objectives, financial situation or needs of individuals. Prospective investors should consider the appropriateness of the information having regard to their own circumstances and seek legal, taxation and financial advice appropriate to their jurisdiction.

Clinical and regulatory information

Clinical data referenced in this Presentation in relation to EVE's patent-pending Libbo is based on formulation design targets and the results of an early, small-scale observational study involving approximately 10 participants. This data has not been generated or reviewed under the conditions of a registered clinical trial and should not be interpreted as demonstrating clinical equivalence, efficacy, safety or bioavailability comparable to any registered reference product. Formal clinical validation, comprising a pilot pharmacokinetic study (dosing targeted Q4 2026) and a planned bioequivalence study, has not been completed as at the date of this Presentation. Onset of action, bioavailability, and any other performance claims remain subject to confirmation through that clinical validation process and may differ materially from the observational data referenced.

Libbo is a prescription medicine. Products supplied under the TGA Special Access Scheme B (SAS-B) pathway are unapproved therapeutic goods and are not listed, registered or otherwise included on the ARTG. The TGA has not evaluated these products for quality, safety or efficacy for ARTG listing or registration purposes. Supply under SAS-B is at the discretion of, and remains the responsibility of, the treating medical practitioner for a specific patient on a case-by-case basis under the applicable regulatory framework.

Compounded medicines are prepared by a licensed pharmacist for an individual patient against a valid prescription, in accordance with the Pharmacy Board of Australia's Guidelines on Compounding of Medicines. Compounded preparations are not listed, registered or otherwise included on the Australian Register of Therapeutic Goods (ARTG) and have not been assessed by the TGA for safety, quality or efficacy. Further detail is set out in the Company's ASX announcement dated 10 November 2026.

Authorisation for release

This Presentation has been authorised for release by the Chief Executive Officer, Mr Ben Rohr.

© EVE HEALTH GROUP 2026

References

Sources supporting the market, clinical and regulatory claims in this presentation.

Previous Disclosure

- "Australian Compounding Agreement Signed for Men's Health Range", 10 November 2026.
- "EVE Initiates Pilot Clinical Study for Libbo ED Film", 16 June 2026. Pilot PK study and pivotal BE pathway.
- "EVE Advances Reformulated Drugs Targeting Global Markets", 10 March 2026.
- "Libbo Launch", 10 February 2026.
- "Libbo Production Complete", 30 January 2026.
- "EVE Signs Telehealth Services Agreement with hubMed", 19 November 2025.
- "Regulatory Milestones met", 21 July 2025.
- "EVE and TeleDocs Clinic Sign National Prescribing Agreement for Erectile Dysfunction Oral Soluble Film and Dysmenorrhea Gummy", 16 June 2025.
- "EVE to Acquire Nextract, Expanding into $5.3B Erectile Dysfunction Market", 14 April 2025. Historical title only; not current market data.

Clinical / Market Sources

- Weber MF et al. Risk factors for erectile dysfunction in a cohort of 108,477 Australian men. MJA 2013;199(2):107–111. doi.org/10.5694/mja12.11548.
- Coherent Market Insights. Erectile Dysfunction Treatment Market Size and Share Analysis: Growth Trends and Forecasts (2026–2033), 28 April 2026. US$5.67B in 2026 (rounded US$5.7B). coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200.
- TGA Special Access Scheme Category B guidance — tga.gov.au.
- Aytaç et al. (1999), The likely worldwide increase in erectile dysfunction — pubmed.ncbi.nlm.nih.gov/10444124/.
- Corona et al. (2016), First-generation PDE5 inhibitor dropout — pubmed.ncbi.nlm.nih.gov/27636710/.
- McMahon (2006), Treating ED when PDE5 inhibitors fail — pubmed.ncbi.nlm.nih.gov/16528082/.
- Corona et al. (2019), Pharmacokinetic issues with first-generation PDE5 inhibitors — pubmed.ncbi.nlm.nih.gov/31350821/.
- Amidon et al. (1995), A theoretical basis for biopharmaceutic drug classification — pubmed.ncbi.nlm.nih.gov/7617530/.

Compounding Channel References

- Australian Bureau of Statistics, Estimated Resident Population by age and sex (ERP_Q), 30 June 2025. abs.gov.au.
- Credence Research, Australia Compounding Pharmacies Market Size, Growth and Forecast 2032 (2024). credenceresearch.com.
- Grand View Research, Australia Compounding Pharmacies Market Size & Outlook, 2030 (2024). grandviewresearch.com.
- Therapeutic Goods Administration, compounded medicines guidance and applicable exemptions. tga.gov.au.
- Pharmacy Board of Australia, Guidelines on Compounding of Medicines (effective 1 October 2024). pharmacyboard.gov.au.

© EVE HEALTH GROUP 2026